围术期使用低剂量氟哌啶醇可安全减少择期微创减重手术后恶心呕吐发作并缩短住院时间
该回顾性研究纳入2018至2022年475例择期微创减重手术患者,15.8%围术期使用低剂量氟哌啶醇。使用氟哌啶醇者术后恶心呕吐发生率更低(41.3% vs 64.3%,p=0.01),围术期外需昂丹司琼更少(34.7% vs 49.8%,p=0.02),中位住院时间更短(27.3 vs 35.8小时,p<0.0001)。作者结论认为将低剂量氟哌啶醇加入减重ERAS方案可减少术后恶心呕吐及额外止吐需求,从而显著缩短住院时间。
要点
- 使用氟哌啶醇者术后恶心呕吐发生率41.3%,未使用者为64.3%(p=0.01)。
- 使用氟哌啶醇者围术期外需昂丹司琼比例34.7%,未使用者为49.8%(p=0.02)。
- 使用氟哌啶醇者中位住院时间27.3小时,未使用者为35.8小时(p<0.0001)。
核心结论
- 作者结论认为,将低剂量氟哌啶醇加入减重ERAS方案可减少术后恶心呕吐发生率及额外止吐覆盖需求,从而显著缩短住院时间,提高术后第1天安全出院的可能性。
研究设计与样本
- 通过回顾性审查2018至2022年接受择期微创减重手术的患者,建立机构减重数据库。
- 共分析475例患者,其中15.8%使用了氟哌啶醇。
- 采用Fisher精确检验、Mann-Whitney检验和ANOVA评估围术期管理对各终点的影响。
主要发现
- 使用氟哌啶醇者围术期外需昂丹司琼的比例为34.7%,未使用者为49.8%(p=0.02)。
- 使用氟哌啶醇者术后恶心呕吐发生率为41.3%,未使用者为64.3%(p=0.01)。
- 使用氟哌啶醇者中位住院时间为27.3小时,未使用者为35.8小时(p<0.0001)。
临床怎么用
- 原文结论认为将低剂量氟哌啶醇加入减重ERAS方案可减少术后恶心呕吐及额外止吐需求并缩短住院时间,原文未据此给出具体用药剂量或给药方案推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: While total intravenous anesthesia (TIVA) protocols include Dexamethasone and Ondansetron prophylaxis, bariatric patients continue to be considered at particularly high risk for postoperative nausea/vomiting (PONV). A multimodal approach for prophylaxis is recommended by the Bariatric Enhanced Recovery After Surgery (ERAS) Society however, there remains a lack of consensus on the optimal strategy to manage PONV in these patients. Haloperidol has been shown at low doses to have a therapeutic effect in treatment of refractory nausea and in PONV prophylaxis in other high risk surgical populations. We sought to investigate its efficacy as a prophylactic medication for PONV in the bariatric population and to identify which perioperative strategies were most effective at reducing episodes of PONV. METHODS: An institutional bariatric database was created by retrospectively reviewing patients undergoing elective minimally invasive bariatric procedures from 2018 to 2022. Demographic data reviewed included age, gender, preoperative body mass index (BMI), ethnicity, and primary language. Primary endpoints included patient reported episodes of PONV, total doses of Ondansetron administered, need for a second antiemetic (rescue medication), complication rate (most commonly readmission within 30 days), and length of stay. Fisher's exact test, Mann-Whitney test, and ANOVA were used to evaluate the effect of perioperative management on various endpoints. RESULTS: A total of 475 patients were analyzed with Haloperidol being utilized in 15.8% of all patients. Patients receiving Haloperidol were less likely to require Ondansetron outside of the immediate perioperative period (34.7% vs. 49.8%, p = 0.02), experienced less PONV (41.3% vs. 64.3%, p = 0.01) and also had a decreased median length of stay (27.3 vs. 35.8 h, p < 0.0001). CONCLUSIONS: Addition of low dose Haloperidol to Bariatric ERAS protocols decreases incidence of PONV and the need for additional antiemetic coverage resulting in a significantly shorter length of stay, increasing the likelihood of safe discharge on postoperative day 1.
引用
- Lam P, Druar N, Swaminathan S, et al. Perioperative use of low dose haloperidol safely reduces episodes of postoperative nausea/vomiting and length of stay following elective minimally invasive bariatric surgery. Surg Endosc. 2023. PMID: 37816995. doi:10.1007/s00464-023-10430-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。